Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014:2014:326545.
doi: 10.1155/2014/326545. Epub 2014 Jun 9.

A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy

Dong-Sup Chung  1 , Hye-Jin Shin  2 , Yong-Kil Hong  2
Affiliations
Review

A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy

Dong-Sup Chung et al. J Immunol Res. 2014.

Abstract

Immunotherapy emerged as a promising therapeutic approach to highly incurable malignant gliomas due to tumor-specific cytotoxicity, minimal side effect, and a durable antitumor effect by memory T cells. But, antitumor activities of endogenously activated T cells induced by immunotherapy such as vaccination are not sufficient to control tumors because tumor-specific antigens may be self-antigens and tumors have immune evasion mechanisms to avoid immune surveillance system of host. Although recent clinical results from vaccine strategy for malignant gliomas are encouraging, these trials have some limitations, particularly their failure to expand tumor antigen-specific T cells reproducibly and effectively. An alternative strategy to overcome these limitations is adoptive T cell transfer therapy, in which tumor-specific T cells are expanded ex vivo rapidly and then transferred to patients. Moreover, enhanced biologic functions of T cells generated by genetic engineering and modified immunosuppressive microenvironment of host by homeostatic T cell expansion and/or elimination of immunosuppressive cells and molecules can induce more potent antitumor T cell responses and make this strategy hold promise in promoting a patient response for malignant glioma treatment. Here we will review the past and current progresses and discuss a new hope in adoptive T cell therapy for malignant gliomas.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Adoptive T cell transfer therapy. (a) Enhancement of tumor-specific T cell function. (b) Modification of the host environment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Han SJ, Zygourakis C, Lim M, Parsa AT. Immunotherapy for Glioma. Promises and challenges. Neurosurgery Clinics of North America. 2012;23(3):357–370. - PubMed
    1. Dietrich P-Y, Dutoit V, Thang NNT, Walker PR. T-cell immunotherapy for malignant glioma: toward a combined approach. Current Opinion in Oncology. 2010;22(6):604–610. - PubMed
    1. Mitchell DA, Fecci PE, Sampson JH. Adoptive immunotherapy for malignant glioma. Cancer Journal. 2003;9(3):157–166. - PubMed
    1. Paul DB, Kruse CA. Immunologic approaches to therapy for brain tumors. Current Neurology and Neuroscience Reports. 2001;1(3):238–244. - PubMed
    1. Schirrmacher V, Schild H-J, Guckel B, Von Hoegen P. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens. Immunology and Cell Biology. 1993;71:311–326. - PubMed

LinkOut - more resources